Every 10-Q that Rapport Therapeutics, Inc. (RAPP) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow RAPP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RAPP filings page.
Rapport Therapeutics, a clinical-stage biotech focused on precision small molecules for neurological and psychiatric disorders, reported a net loss of $56,615 (in thousands) for the three months ended June 30, 2026, and $76,472 (in thousands) for the six-month period. Operating expenses rose sharply, with research and development at $51,414 (in thousands) for the quarter as the company advanced its lead AMPA receptor negative allosteric modulator, RAP-219, and other programs.
Collaboration revenue of $20,000 (in thousands) in the first half of 2026 came entirely from an upfront payment under a license agreement granting Tenacia Biotechnology rights to RAP-219 in mainland China, Hong Kong, Macau and Taiwan. Cash, cash equivalents and short-term investments totaled $436.1 million as of June 30, 2026, which management expects will fund operating and capital needs for at least 12 months from the financial statement issuance date; the company nonetheless anticipates continued losses and the need for additional financing over time.
Rapport Therapeutics reported its first collaboration revenue and a narrower quarterly loss while accelerating its neurology pipeline. For the three months ended March 31, 2026, collaboration revenue was $20,000 (thousand) driven by a new regional licensing deal, compared with none a year earlier. Research and development expenses rose to $32,716 thousand and selling, general and administrative costs to $11,499 thousand, reflecting expanded clinical activity and public-company infrastructure. Net loss improved to $19,857 thousand, or $0.42 per share, versus a $24,063 thousand loss, or $0.68 per share, in the prior-year quarter. Cash, cash equivalents and short-term investments totaled $476,782 thousand as of March 31, 2026, supported by a $269,400 thousand follow-on equity offering completed in 2025, giving the company resources to fund late-stage trials of lead candidate RAP-219 for focal onset seizures and bipolar mania and to advance earlier programs.
Rapport Therapeutics (RAPP) filed its Q3 2025 10‑Q, reporting a net loss of $26.9 million (EPS $(0.71)) as operating expenses rose with pipeline investment. Research and development was $22.3 million and general and administrative was $7.7 million for the quarter.
The balance sheet strengthened following a September follow‑on equity raise. As of September 30, cash and cash equivalents were $251.4 million and short‑term investments were $261.7 million, for total liquidity of about $513.0 million. Stockholders’ equity was $511.6 million. Net cash used in operations for the first nine months was $62.8 million.
In September 2025, the company completed an underwritten public offering of 11,057,692 shares at $26.00 per share for net proceeds of $269.4 million. Common shares outstanding were 47,650,216 as of September 30, 2025, and 47,661,138 as of November 3, 2025. The company highlights typical biotech risks, including clinical, regulatory and financing uncertainties, and references the FDA clinical hold on its RAP‑219 Phase 2 proof‑of‑concept trial as a risk factor.